Methods

Study Population
Our hospital considers all patients with ST-segment elevation (ST-se) AMI as eligible for primary percutaneous coronary intervention (PCI). The present study included consecutive ST-se AMI patients admitted for primary PCI to our hospital between September 2003 and April 2005. An estimated sample size of 225 patients was based on the effective size with =0.05, a power of 80%, a difference in 30-day mortality in AMI patients with G/G vs non-G/G genotype of 4% and also assuming a 20% rate of protocol violations and incomplete follow-up.
To circumvent other potential influences on serum level of high-sensitivity C-reactive protein (hs-CRP), the present study excluded patients with a history of recent surgery or trauma during the preceding 2 months, renal insufficiency (creatinine >1.5 mg/dl), malignancy, febrile disorders, acute or chronic inflammatory disease at study enrollment time, autoimmune diseases with or without immunosuppressive therapy, or a prior myocardial infarction onset of <2 months. Thus, 250 consecutive patients (group 1) of any age, who presented with AMI of <12 h duration and underwent primary PCI, were prospectively investigated and recruited within a period of 20 months.
Between September 2003 and April 2005, patients (group 2) who underwent elective PCI due to angina pectoris were prospectively enrolled and matched for age, gender, hypertension, diabetes mellitus, current smoking and hypercholesterolemia, and served as control subjects for coronary artery obstructive disease. For the purpose of the present study, patients with the following angiographic morphologic features were excluded: (1) irregular morphology; (2) overhanging or abrupt edges in the vessel wall; (3) ulcerative plaque; and (4) filling defects consistent with intracoronary thrombus in the stenotic lesion, which indicated vulnerable/ ruptured plaque. Patients with abnormal elevation of troponin I levels before PCI were also excluded. Therefore, a total of 203 consecutive patients were enrolled within the 20-month study period.
Additionally, 50 subjects (group 3) who underwent coronary angiographic study due to chest pain with normal coronary angiographic findings were matched for age, gender, hypertension, diabetes mellitus, current smoking and hypercholesterolemia, between September 2003 and December 2005, and served as control subjects for normal coronary arteries. Informed consent was obtained from each study subject. The Institutional Review Committee on Human Research at our institution approved the study protocol.
Procedure and Protocol
A transradial artery approach using a 6-French arterial sheath was routinely applied for the treatment of AMI at our hospital unless the Allen's test was positive on both hands. A 6-French Kimny Miniradial guiding catheter (Boston Scientific, Scimed, Inc, Maple Grove, MN, USA) was used for diagnosis and primary PCI.
Clopidogrel (300 mg loading dose before stenting then 75 mg/day) was given for patients who underwent primary stenting. Aspirin (100 mg orally once a day) was given indefinitely to each patient. Other commonly prescribed drugs were angiotensin-converting enzyme inhibitors, -blockers, isornitrate and diuretics.
Blood Sampling and Laboratory Investigations
For the purpose of the present study, blood samples were prospectively drawn following vascular puncture for serum hs-CRP levels, white blood cell (WBC) count, creatinine and other biochemistry examinations, and the study of CTLA-4 genotypes.
The hs-CRP was measured by immunonephelometry using the BN™ system (Dade Behring Inc, Newark, DE, USA). The lower detection limit was <0.15 mg/L. The intraindividual variability of serum hs-CRP levels was assessed in 3 groups of patients, the mean intra-assay coefficients of variance were 2.91%, 2.74% and 2.61%, respectively.
Determining Genotype Using the PCR-Restriction Fragment Length Polymorphism Method
The frequency distribution of SNP (A/A, A/G and G/G) and allele (A or G) of the CTLA-4 gene were examined using the PCR-restriction fragment length polymorphism method. Procedural details have been described previously. 19 Briefly, DNA was extracted from peripheral blood leukocytes using a DNA extraction kit. The A/G SNP at the exon 1 position of the CTLA-gene was genotyped using the PCR-restriction fragment length polymorphism method. The used primers were 5'-GGCTTGCCTTGGATTTCAA-CGGC-3' and 5'-GCTTCCAAAAGTCTCACTCACC-3'.
The amplified products were digested with the restriction enzyme, Ita1, and analyzed on the 3% agarose gel. The G allele corresponded to the presence of 2 88-bp and 41-bp fragments generated using Ita1 digestion. The A allele corresponded to the 129-bp uncleaved fragment with no Ita1 site.
Definitions and Data Collection
AMI was defined as the presence of typical chest pain for more than 30 min with ST-se >1 mm in 2 or more consecutive precordial or inferior leads. Unsuccessful reperfusion was defined as failure to achieve normal blood flow after PCI of the infarct-related artery. Reperfusion time was defined as the time from chest pain onset to the first balloon inflation. Detailed in-hospital and follow-up data, including age, sex, coronary risk factors, serial MB fraction of creatin kinase levels, WBC counts, creatinine level, body temperature, Killip score on admission and severity of congestive heart failure (CHF) were collected prospectively and entered into a computer database. Angiographic findings, namely blood flow in the culprit coronary artery, lesion length, minimum lumen diameter (MLD), reference lumen diameter (RLD) and number of diseased vessels, were also collected and entered into the database.
End Points and Statistical Analysis
The endpoint of the present study was the 30-day composite occurrence of major adverse clinical outcomes (MACO), including advanced CHF (defined as New York Heart Association functional class ≥ 3), acute or sub-acute re-occlusion of infract-related artery or 30-day mortality.
Data were expressed as mean ± SD. Continuous data were analyzed using one-way ANOVA or the t-test, and categorical data were analyzed using the chi-square test. Statistical analysis was performed using SAS statistical software for Windows version 8.2 (SAS institute, Cary, NC, USA). A value of p<0.05 was considered statistically significant. (Table 1 ) Table 1 summarizes the clinical characteristics of the 3 groups of patients. No significant difference was found among the 3 groups for age, gender, hypertension, diabetes mellitus or hypercholesterolemia. However, the hs-CRP level and the WBC count were significantly higher in group 1 patients than in group 2 and group 3 patients, and the WBC count was higher in group 2 patients than in group 3 patients. Angiographic findings demonstrate that no significant difference was observed in multi-vessel disease and RLD between group 1 and group 2 patients. However, the MLD and lesion length were significantly higher in group 1 than in group 2 patients.
Results
Clinical Characteristics of 503 Patients
Multiple stepwise logistic regression analysis of the enrollment variables, including age, gender and conventional risk factors for coronary artery disease on Table 1 , and G/G, A/G and A/A genotypes demonstrated that G/G was the only independent predictor of the occurrence of ST-se AMI (odds ratio =2.31, 95% confidence interval =1.57-3.39, p<0.0001). (Table 2 ) Table 2 shows the frequencies of the genotypes and alleles of the CTLA-4 gene among the 3 groups of patients.
Comparison of the Frequencies of the Genotypes and A/G Alleles of CTLA-4 Gene Among 3 Groups of Patients
Group 1 patients had significantly more G/G genotypes and G alleles than group 2 and group 3 patients. (Table 3) Group 1 had no significant differences regard with age gender, coronary artery disease risk factors, previous stroke or myocardial infarction, cardiogenic shock upon presentation, reperfusion time or final Thrombolysis In Myocardial Infarction-3 flow in patients with G/G, A/G or A/A genotypes. Additionally, angiographic findings demonstrated that there was no significant difference in MLD or RLD between patients with G/G, A/G or A/A genotypes. However, patients with the G/G genotype had significantly higher levels of circulating hs-CRP and higher WBC counts than patients with A/G or A/A genotypes. Furthermore, patients with the G/G genotype had significantly higher lesion lengths and multi-vessel disease rates. Moreover, patients with the G/G genotype had a much higher incidence of advanced CHF and 30-day mortality than those patients with A/G or A/A genotypes.
Comparison of Clinical Variables Among Group 1 Patients With Different Genotypes
Determinants of 30-Day MACO and 30-Day Mortality in Group 1 Patients (Tables 4-6)
Results of univariate analysis demonstrate that the G/G genotype, but not the A/G or A/A genotype, was significantly associated with an increased 30-day MACO. Additionally, circulating levels of hs-CRP and WBC count were strongly correlated with increased 30-day MACO. Moreover, cardiogenic shock upon presentation was significantly predictive of 30-day MACO, whereas successful reperfusion was a determinant factor of reduced 30-day MACO.
Multiple stepwise logistic regression analysis demonstrates that cardiogenic shock, hs-CPR levels and WBC count were independent predictors of 30-day MACO. Additionally, cardiogenic shock along with hs-CRP and advanced CHF was independently predictive of 30-day mortality.
Discussion
The present study, in which the frequency distribution of SNP (A/A, A/G and G/G) of the CTLA-4 gene was examined in 503 Chinese study subjects in different clinical settings, produced several significant implications. First, the G/G genotype was independently predictive of ST-se AMI. Second, the incidence of G/G was significantly higher in group 1 patients than in both group 2 and 3 patients. Third, in the group 1, patients with the G/G genotype had a 30-day mortality rate >3.5 times higher than that of patients with A/G or A/A genotype. Fourth, hs-CRP and WBC, 2 indices of inflammatory biomarkers, were independently predictive of 30-day MACO.
Convincing studies have reported that inflammation plays a crucial role in the cell biology of atherosclerosis. 1, 2, 5, 23, 24 T cells, as effectors of adaptive immunity antigen, specifically modulate the progression and activity of atherosclerotic plaque. In the culprit lesions of ACS, the percentage of activated T cells is significantly increased. 25 Activated T cells differentiate into type 1 helper T effector cells and begin producing the macrophage-activating cytokine interferon-. 26 In addition, T cell cytokines stimulate the production of pro-inflammatory factors that enhance the production of pro-inflammatory cytokines and CRP. 27 These in turn, initiate a potent inflammatory cascade in both atherosclerotic plaque and systemic circulation. 27 Pathologic and immunohistochemical staining studies have clearly shown a preponderance of inflammatory cells in the ruptured plaques of patients who have died of ACS. 6, 28 In fact, inflammation does not always cause endothelial dysfunction, atherosclerotic plaque formation or plaque rupture. Therefore, a balance between the inflammatory and anti-inflammatory system must be present in healthy subjects. But this may also indicate either an over-reactive immune response or an inherent deficiency in immune suppression in patients with clinical settings of AMI or other autoimmune diseases. 2, 6, 11, 17, 18 Basic research demonstrates that T cell activation and the generation of protective immunity are the result of a balance between positive vs negative signals. 29 CTLA-4 is a co-stimulatory molecule that is expressed on activated T lymphocytes and is an important negative regulator of Tcell activation. 29 Increasing evidence shows that CTLA-4 is a very important molecule for down-regulating T-cell expansion and cytokine production. [19] [20] [21] [22] Additionally, CTLA-4 expression on a T-cell has been identified as strongly influencing the course or presentation of an ongoing immune process. [30] [31] [32] Furthermore, an impressive correlation between CTLA-4 gene A-G polymorphism and Graves' disease has been found in Asian patients. 19, 33, 34 However, whether an association exists between the CTLA-4 gene A-G polymorphism and ST-se AMI in Chinese population remains unknown. To the best of our knowledge, ours is the first cohort study with a large sample size to delineate the frequency distribution of the SNP (A/A, A/G and G/G) and  alleles (A or G) of the CTLA-4 gene in ST-se AMI patients. One of the most important findings in the present study was that the incidence of G/G was significantly higher in group 1 patients than in group 2 and group 3 patients. Additionally, the circulating levels of hs-CRP and WBC count were also significantly higher in group 1 patients than in the other 2 groups. Furthermore, among group 1 patients, hs-CRP level, WBC count, multi-vessel disease and lesion length were remarkably higher in G/G genotype patients than in A/G or A/A genotype patients. Therefore, these findings raise the hypothesis that an over-reactive inflammatory response, due to an inherent immune suppression defect, should be present in G/G genotype patients. This hypothesis is further supported by the finding of the present study that G/G genotype was found to be independently predictive of plaque rupture/AMI. An association between increased circulating levels of inflammatory markers, multivessel disease and multiple complex stenoses has been established. [34] [35] [36] [37] Additionally, convincing evidence shows that inflammation directly participates in plaque rapture in patients with ACS. 1,2,5-9,11,24,28 Accordingly, our conclusion is further supported by these studies. 1, 2, [5] [6] [7] [8] [9] 11, 24, 28, 35, 36 Previous studies have shown that circulating levels of hs-CRP and WBC count are strongly predictive of unfavorable clinical outcomes in patients following AMI. 38, 39 Importantly, the present study found that both inflammatory markers of hs-CRP and WBC count are independently predictive of 30-day MACO. Thus, we conclude that the G/G genotype reflects an inappropriate immune response in the course of inflammatory process and can be translated into a phenotype presentation of significantly increased circulating levels of hs-CRP and WBC counts, as well as an untoward clinical outcome. Accordingly, our findings strengthen the findings observed by previous studies. 35, 36 Previous studies have revealed an association of cardiogenic shock and CHF with unfavorable clinical outcomes. [40] [41] [42] The present study, has found that cardiogenic shock and advanced CHF were independent determinants of 30-day mortality, thus confirming the findings observed by the previous studies. [40] [41] [42] A strong association between an increase in circulating levels of interleukin-18, an inflammatory cytokine, and cardiogenic shock has been recently reported in patients with AMI undergoing primary PCI. 43 Thus, we speculate the current results implicate that the G/G genotype increased risk of unfavorable prognostic outcomes following AMI via an interaction between inflammatory response and cardiogenic shock.
Study Limitation
First, the conclusions of the present study are based on a study of Chinese population undergoing primary PCI. With respect to different races, even a similar defect of genotype may have a different disease presentation phenotype. Therefore, caution should be used when extrapolating the results of the present study to AMI patients' of different ethnic groups for risk stratification. Second, without routine use of the intra-vascular ultrasonic study in the group 2 patients, patients with plaque ruptures in the obstructive lesions were not completely excluded.
Conclusion
The G/G genotype polymorphism of the CTLA-4 contributes to the pathogenesis of plaque rupture, increased risk Circulation Journal Vol.71, August 2007 of AMI and unfavorable prognostic outcomes following AMI via increases in the incidence of cardiogenic shock and inflammatory responses.
